Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -391.26% is in line with its 3-year average of -367.84%, around the middle of its 3-year range (-718.46%–-67.48%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.91% above its 12-month average of -470.87%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -391.26%.
RETURN ON EQUITY (ROE)
-391.26%
RETURN ON EQUITY (ROE) AVG TTM
-470.87%
RETURN ON EQUITY (ROE) AVG 3Y
-367.84%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+16.91%
CURRENT VS 3Y AVG
-6.37%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 630 covered companies
CURRENT VS SECTOR MEDIAN
-873.17%
vs the sector median at left
FibroBiologics, Inc. Common Stock
Market Cap
$2.52M
Return on Equity (ROE)
-391.26%
TTM Avg
-470.87%
3Y Avg
-367.84%
5Y Avg
N/A
Market Cap
$2.57M
Return on Equity (ROE)
-554.01%
TTM Avg
-109.66%
3Y Avg
1542.76%
5Y Avg
920.25%
Market Cap
$2.41M
Return on Equity (ROE)
-261.73%
TTM Avg
-293.81%
3Y Avg
-189.35%
5Y Avg
-145.76%
Market Cap
$2.53M
Return on Equity (ROE)
-402.92%
TTM Avg
-276.14%
3Y Avg
-197.40%
5Y Avg
-116.89%
Market Cap
$2.59M
Return on Equity (ROE)
N/A
TTM Avg
-419.35%
3Y Avg
-396.40%
5Y Avg
-293.00%
Market Cap
$2.63M
Return on Equity (ROE)
-657.69%
TTM Avg
-358.53%
3Y Avg
-220.37%
5Y Avg
-149.08%
Market Cap
$2.35M
Return on Equity (ROE)
-69.79%
TTM Avg
-83.20%
3Y Avg
-70.37%
5Y Avg
-0.36%
Market Cap
$2.38M
Return on Equity (ROE)
-75.70%
TTM Avg
-349.85%
3Y Avg
-22.96%
5Y Avg
-60.31%
Market Cap
$2.25M
Return on Equity (ROE)
-1160.10%
TTM Avg
-528.10%
3Y Avg
-389.86%
5Y Avg
-336.02%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| FibroBiologics, Inc. Common Stock (FBLG) | $2.52M | -391.26% | -470.87% | -367.84% | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.57M | -554.01% | -109.66% | 1542.76% | 920.25% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.41M | -261.73% | -293.81% | -189.35% | -145.76% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.53M | -402.92% | -276.14% | -197.40% | -116.89% |
| Nuwellis, Inc. (NUWE)vs › | $2.59M | N/A | -419.35% | -396.40% | -293.00% |
| iSpecimen Inc. (ISPC)vs › | $2.63M | -657.69% | -358.53% | -220.37% | -149.08% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.35M | -69.79% | -83.20% | -70.37% | -0.36% |
| Onconetix, Inc. (ONCO)vs › | $2.38M | -75.70% | -349.85% | -22.96% | -60.31% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.25M | -1160.10% | -528.10% | -389.86% | -336.02% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.00M | N/A | -236.13% | -104.67% | -48.54% |
ROE
-391.3%
ROA
-228.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -391.26% |
| 2026-03-31 | -718.46% |
| 2025-12-31 | -302.89% |
| 2025-03-31 | -326.26% |
| 2024-12-31 | -408.08% |
| 2024-09-30 | -649.58% |
| 2023-09-30 | -78.69% |
| 2023-06-30 | -67.48% |
